Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer: Lung cancer

Tina Cascone; William N. William

doi:10.1038/s41571-024-00976-x

Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer: Lung cancer

Tina Cascone
, William N. William

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

5 Scopus citations

Abstract

As one of the first studies testing perioperative anti-PD-(L)1 antibodies in resectable non-small-cell lung cancer (NSCLC), NADIM now confirms, in its final report, impressive 5-year clinical outcomes and that a pCR following neoadjuvant therapy translates into improved long-term survival. These data support the development of novel, personalized treatments for locally advanced resectable NSCLC.

Original language	English (US)
Pages (from-to)	81-82
Number of pages	2
Journal	Nature Reviews Clinical Oncology
Volume	22
Issue number	2
DOIs	https://doi.org/10.1038/s41571-024-00976-x
State	Published - Feb 2025

ASJC Scopus subject areas

Oncology

Access to Document

10.1038/s41571-024-00976-x

Cite this

@article{5401dbe2121e4de4bc1d3fc2b5f50af4,

title = "Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer: Lung cancer",

abstract = "As one of the first studies testing perioperative anti-PD-(L)1 antibodies in resectable non-small-cell lung cancer (NSCLC), NADIM now confirms, in its final report, impressive 5-year clinical outcomes and that a pCR following neoadjuvant therapy translates into improved long-term survival. These data support the development of novel, personalized treatments for locally advanced resectable NSCLC.",

author = "Tina Cascone and William, \{William N.\}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Limited 2024.",

year = "2025",

month = feb,

doi = "10.1038/s41571-024-00976-x",

language = "English (US)",

volume = "22",

pages = "81--82",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer

T2 - Lung cancer

AU - Cascone, Tina

AU - William, William N.

N1 - Publisher Copyright: © Springer Nature Limited 2024.

PY - 2025/2

Y1 - 2025/2

N2 - As one of the first studies testing perioperative anti-PD-(L)1 antibodies in resectable non-small-cell lung cancer (NSCLC), NADIM now confirms, in its final report, impressive 5-year clinical outcomes and that a pCR following neoadjuvant therapy translates into improved long-term survival. These data support the development of novel, personalized treatments for locally advanced resectable NSCLC.

AB - As one of the first studies testing perioperative anti-PD-(L)1 antibodies in resectable non-small-cell lung cancer (NSCLC), NADIM now confirms, in its final report, impressive 5-year clinical outcomes and that a pCR following neoadjuvant therapy translates into improved long-term survival. These data support the development of novel, personalized treatments for locally advanced resectable NSCLC.

UR - https://www.scopus.com/pages/publications/85211451288

UR - https://www.scopus.com/pages/publications/85211451288#tab=citedBy

U2 - 10.1038/s41571-024-00976-x

DO - 10.1038/s41571-024-00976-x

M3 - Comment/debate

C2 - 39627503

AN - SCOPUS:85211451288

SN - 1759-4774

VL - 22

SP - 81

EP - 82

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 2

ER -

Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer: Lung cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this